News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
226,877 Results
Type
Article (5184)
Company Profile (17)
Press Release (221676)
Section
Business (82392)
Career Advice (463)
Deals (15080)
Drug Delivery (8)
Drug Development (19300)
Employer Resources (30)
FDA (3698)
Job Trends (3926)
News (120544)
Policy (7566)
Tag
Academia (299)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14831)
ALS (22)
Alzheimer's disease (248)
Antibody-drug conjugate (ADC) (14)
Approvals (3722)
Artificial intelligence (46)
Autoimmune disease (3)
Automation (4)
Bankruptcy (97)
Best Places to Work (2885)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (12)
Brain cancer (7)
Breast cancer (51)
Cancer (500)
Cardiovascular disease (26)
Career advice (395)
Career pathing (3)
CAR-T (36)
Cell therapy (112)
Cervical cancer (2)
Clinical research (16278)
Collaboration (186)
Compensation (196)
Complete response letters (2)
COVID-19 (325)
CRISPR (11)
C-suite (115)
Cystic fibrosis (16)
Data (581)
Depression (7)
Diabetes (48)
Diagnostics (2054)
Digital health (4)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (7)
Drug shortages (1)
Duchenne muscular dystrophy (14)
Earnings (41362)
Editorial (2)
Employer branding (6)
Employer resources (31)
Events (38084)
Executive appointments (333)
FDA (4046)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (197)
Gene editing (19)
Generative AI (2)
Gene therapy (55)
GLP-1 (116)
Government (427)
Guidances (90)
Healthcare (5053)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (18)
Indications (8)
Infectious disease (341)
Inflammatory bowel disease (25)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (54)
IPO (7853)
IRA (3)
Job creations (1125)
Job search strategy (362)
Kidney cancer (7)
Labor market (5)
Layoffs (103)
Leadership (5)
Legal (2339)
Liver cancer (18)
Lung cancer (64)
Lymphoma (36)
Management (10)
Manufacturing (55)
MASH (30)
Medical device (3867)
Medtech (3868)
Mergers & acquisitions (7455)
Metabolic disorders (137)
Multiple sclerosis (9)
NASH (6)
Neurodegenerative disease (13)
Neuropsychiatric disorders (1)
Neuroscience (356)
NextGen: Class of 2025 (1681)
Non-profit (733)
Now hiring (3)
Obesity (58)
Opinion (33)
Ovarian cancer (21)
Pain (14)
Pancreatic cancer (16)
Parkinson's disease (30)
Partnered (4)
Patents (25)
Patient recruitment (35)
Peanut (5)
People (24710)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (4876)
Phase II (7083)
Phase III (5657)
Pipeline (741)
Policy (9)
Postmarket research (626)
Preclinical (1887)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (75)
Real estate (1879)
Recruiting (8)
Regulatory (5209)
Reports (17)
Research institute (302)
Resumes & cover letters (68)
Rett syndrome (6)
Schizophrenia (22)
Series A (31)
Series B (25)
Sickle cell disease (7)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (4)
Startups (1017)
Stomach cancer (1)
Supply chain (10)
Tariffs (5)
Vaccines (38)
Venture capitalists (2)
Weight loss (23)
Women's health (1)
Date
Today (68)
Last 7 days (335)
Last 30 days (1162)
Last 365 days (9855)
2025 (3959)
2024 (11126)
2023 (13239)
2022 (18732)
2021 (19820)
2020 (18383)
2019 (13275)
2018 (10233)
2017 (10054)
2016 (9190)
2015 (12132)
2014 (9594)
2013 (7709)
2012 (8334)
2011 (8801)
2010 (8637)
Location
Africa (186)
Alabama (14)
Alaska (2)
Arizona (61)
Arkansas (1)
Asia (11718)
Australia (1616)
California (2223)
Canada (760)
China (112)
Colorado (88)
Connecticut (100)
Delaware (70)
Europe (24707)
Florida (316)
Georgia (35)
Idaho (23)
Illinois (118)
India (7)
Indiana (73)
Iowa (3)
Japan (79)
Kansas (24)
Kentucky (11)
Louisiana (6)
Maine (42)
Maryland (244)
Massachusetts (1740)
Michigan (88)
Minnesota (147)
Mississippi (1)
Missouri (23)
Montana (16)
Nebraska (12)
Nevada (26)
New Hampshire (16)
New Jersey (628)
New Mexico (5)
New York (516)
North Carolina (350)
North Dakota (4)
Northern California (1092)
Ohio (63)
Oklahoma (5)
Oregon (4)
Pennsylvania (383)
Puerto Rico (1)
Rhode Island (13)
South America (277)
South Carolina (9)
Southern California (787)
Tennessee (45)
Texas (254)
United States (7884)
Utah (66)
Virginia (51)
Washington D.C. (11)
Washington State (187)
West Virginia (2)
Wisconsin (26)
226,877 Results for "incyte corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Incyte Backs Out of Immuno-Oncology Pact With Agenus
The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including TIM-3, LAG-3, OX40 and GITR.
February 12, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Incyte’s $750M Escient Bet Flops as Skin Disease Assets Stumble
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and further erode confidence that the biotech can effectively mitigate the impacts of Jakafi’s loss of exclusivity in the coming years, according to analysts.
November 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Incyte to Report First Quarter Financial Results
April 10, 2025
·
1 min read
Press Releases
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2025
May 8, 2025
·
1 min read
Press Releases
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 29, 2025
·
19 min read
Press Releases
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
April 25, 2025
·
4 min read
Cancer
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data
Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos will deprioritize the development of inupadenant after it failed to meet the biotech’s clinical bar in a Phase II study of metastatic non-small cell lung cancer.
December 13, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Incyte to Present at Upcoming March 2025 Investor Conferences
February 19, 2025
·
1 min read
Press Releases
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
May 15, 2025
·
14 min read
Press Releases
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2025
·
7 min read
1 of 22,688
Next
